F1000Research F1000Research 2046-1402 F1000 Research Limited London, UK 10.12688/f1000research.24441.1 Opinion Article Articles SARS-CoV-2 and hypokalaemia: evidence and implications

[version 1; peer review: 1 not approved]

 Mabillard Holly Writing – Original Draft Preparation 1 Sayer John A. Conceptualization Writing – Original Draft Preparation Writing – Review & Editing https://orcid.org/0000-0003-1881-3782 a 1 2 3 Renal Services, The Newcastle Hospitals NHS Foundation Trust,, Newacstle upon Tyne, Tyne and Wear, NE77DN, UK Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, Tyne and Wear, NE13BZ, UK NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, Tyne and Wear, NE45PL, UK john.sayer@ncl.ac.uk

No competing interests were disclosed.

 10 6 2020 2020 9 587 3 6 2020 Copyright: © 2020 Mabillard H and Sayer JA 2020 This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The global pandemic secondary to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is leading to unprecedented global morbidity and mortality. With a bewildering array of complications, renal involvement in various forms is common, including serum electrolyte derangements. Hypokalaemia secondary to SARS-CoV-2 was common in a reported Chinese cohort. Here we review the emerging evidence on hypokalaemia and SARS-CoV-2 infection, the potential pathophysiological mechanisms based on early clinical and histopathological data and important clinical implications. Mechanisms of hypokalaemia are multifactorial and so the electrolyte disturbance can be difficult to avoid. We provide further support to the theory of renin-angiotensin-aldosterone (RAS) activation, discuss the strengths and weaknesses of implicating RAS involvement and highlight the importance of calculating the transtubular potassium gradient to identify those at risk of hypokalaemia and its complications.

 Hypokalaemia SARS-CoV-2 ACE-2 transtubular potassium gradient alkalosis Northern Counties Kidney Research Fund Kidney Research UK JAS is supported by Kidney Research UK and Northern Counties Kidney Research Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Introduction

The global pandemic secondary to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is leading to unprecedented global morbidity and mortality. Anecdotal data and clinical observation from patients with the World Health Organization named disease coronavirus disease 2019 (COVID-19) has highlighted a bewildering array of presentations and pathologies. These include respiratory complications (acute hypoxic respiratory failure, severe pneumonia, acute respiratory distress syndrome (ARDS) and pulmonary fibrosis) 1 , cardiovascular complications (myocardial injury, myocarditis, cardiomyopathy, cardiac tamponade, acute myocardial infarction, heart failure, dysrhythmias and venous thromboembolic events) 2 , neurological complications (anosmia, myopathy, acute stroke, Guillain-Barre syndrome and encephalopathy) 3 , acute liver and/or pancreatic injury 4 , cytokine storm syndrome, septic shock, DIC, diarrhoea, Kawasaki-like disease 5 and renal complications (acute tubular injury, rhabdomyolysis, proteinuria, secondary focal segmental glomerulosclerosis and possible renin-angiotensin-aldosterone system activation) 6 .

SARS-CoV-2 may affect the kidneys directly and indirectly by both renal and renin-angiotensin-aldosterone system (RAS) involvement. What is uncertain are the exact pathophysiological mechanisms that play a role in this. Early reports have suggested that hypokalaemia may be seen frequently in patients infected with the SARS-CoV-2 virus. Here we aim to review the evidence and the potential clinical implications of this well recognised but potentially serious electrolyte disturbance in patients with SARS-CoV-2 infection and touch on renal features of the infection discovered so far.

Firstly, it is important to highlight how transmission of the virus occurs in humans. The SARS-CoV-2 spike protein enters host cells via the angiotensin-converting enzyme 2 (ACE2) receptor on the surface of pulmonary type 2 alveolar cells 7, 8 . ACE2 is crucial to counter-regulate RAS and shares approximately 60% homology with ACE. RAS pathway components are co-expressed in most organs and tissues in the body and communicate via both paracrine and autocrine signalling. ACE2 converts angiotensin-II into angiotensin-(1-7), which acts on the Mas receptor expressed on a variety of tissue cell lineages relevant to cardiovascular disease in addition to type 2 alveolar epithelial cells. It lowers blood pressure through vasodilation and promotion of renal sodium and water excretion and it also attenuates inflammation by producing nitric oxide. Meanwhile, ACE converts angiotensin-I to angiotensin-II which has directly opposing effects to signalling mediated by ACE2. Angiotensin-II acts at the type 1 angiotensin receptor (AT1R) to increase blood pressure by the induction of vasoconstriction and renal sodium and water reabsorption. This also creates oxidative stress which promotes inflammation and fibrosis. The balance between these two opposing pathways determines potential tissue injury, predominantly in the heart and kidneys 7, 8 . Not only has the ACE2 receptor found to be used for host cell entry by the SARS-CoV virus, but the affinity for SARS-CoV-2 is 10-20-fold higher 9 . During host cell entry, proteolytic cleavage of ACE2 by transmembrane serine protease 2 (TMPRSS2) occurs which is thought to suppress ACE2 expression. This in theory would lead to a reduction in angiotensin-(1-7) generation and angiotensin-II levels would increase resulting in oxidative-stress mediated tissue damage and hypertension 7, 8 . This mechanism resulting in lung parenchymal injury has already been demonstrated in mice injected with SARS-CoV-2 virus 10 .

Involvement of the RAS pathway has therefore been speculated as a mechanism to lead to more severe COVID-19 disease and patients with severe disease were more likely to have hypertension, chronic kidney disease (CKD), diabetes mellitus and cardiovascular disease than those with milder disease. This is, however not confirmed and is preliminary data that may be the subject of bias with disregard of age as a potential confounding factor 8 .

Hypokalaemia is known to cause muscle weakness, paraesthesia, thirst, muscle cramps and weakness, but hypokalaemia is an important complication of any disease due to it being a potentially life-threatening condition 11 . In fact, the incidence of ventricular fibrillation has been shown to be fivefold higher in patients with hypokalaemia compared to those with hyperkalaemia 12 . Furthermore, inadequate management of hypokalaemia has been identified in 24% of hospitalised patients 13 , reiterating that we need to be even more vigilant with the management of this life-threatening condition during a pandemic where resources are even more scarce.

What is the evidence for hypokalaemia in SARS-CoV-2 infection so far?

The release of a pre-print retrospective Chinese study initially sparked interest into hypokalaemia as a potentially prevalent biochemical disturbance in SARS-CoV-2 infection 14 . This was released around a similar time to concerns around RAS inhibitors and SARS-CoV-2 where speculation that RAS inhibitors may increase risk of SARS-CoV-2 infection and its severity due to the knowledge that ACE2 is the viral binding site for host cell entry. It has been stressed by multiple organisations globally that RAS inhibitors should be continued unless otherwise medially indicated as the risks of stopping these important drugs have numerous serious complications to the patient. This study claimed that hypokalaemia was prevalent amongst SARS-CoV-2 infected patients, affecting 108 of 175 patients (62%) that had a serum potassium of <3.5 mmol/l and only 10 patients had a serum K >4.0 mmol/l which is the value required for those with myocardial dysfunction. Of the patients, 22% had severe hypokalaemia (serum potassium <3.0 mmol/l). In total, 11% of all patients and 28% of those with severe hypokalaemia displayed metabolic alkalosis (pH >7.45) compared to 4% with normokalaemia suggesting the possibility of RAS activation. The study suggested that the hypokalaemia was not due to gastrointestinal (GI) loss of potassium as only a small proportion of patients had GI symptoms, there was no significant difference between serum potassium in those with or without diarrhoea and significant urinary potassium wasting was shown. A total of 20 patients had a spot urine potassium/creatinine ratio and there were significantly higher urinary potassium/creatinine ratios in those with hypokalaemia compared with normokalaemia. The study reported that the degree of hypokalaemia correlated with severity of SARS-CoV-2 symptoms and they suggested that hypokalaemia can be difficult to correct as seen in two patients because the renal potassium wasting persists until clinical recovery from the virus. This study is relatively small, limited to a Chinese population and did not disclose medications or diuretic use which could be a significant confounding factor here. As diuretics (especially “loop” diuretics) are used to improve oxygenation in patients with ARDS, some of these patients may well have been prescribed them. It was postulated that hypokalaemia in these patients is due to the effects of increased angiotensin-2 resulting from the proteolytic cleavage of ACE2 from virion invasion of the host although this conclusion cannot be made without measuring components of the RAS system in these patients. Further studies including declaration of medications/diuretic use and measurement of components of the RAS pathway are necessary to make conclusions about aetiology of hypokalaemia in SARS-CoV-2 infection although hypokalaemia was clearly a clinical risk in these patients that should be communicated to the medical community.

A study performed in Hong Kong during the 2003 SARS-CoV epidemic compared symptoms and laboratory findings in SARS-CoV RT-PCR swab-positive patients to negative patients 15 . Hypokalaemia was present in 41.3% of RT-PCR positive patients and was reported as a ‘common laboratory finding’. It was also suggested in this paper that the hypokalaemia was due to the increased effects of angiotensin-2 but, again, the RAS components were not measured in patients. In contrast, the largest SARS-CoV-2 case series so far (1099 patients included) did not demonstrate any major difference in serum potassium between those with mild and those with severe disease 16 . Serum potassium was mostly reported as normal in this cohort. SARS-CoV was found in the urine in one patient but urine was not routinely tested for the virus in this cohort.

 Not all patients with hyperaldosteronism develop hypokalaemia

The theory of RAS activation causing hypokalaemia is popular, however it is recognised that hyperaldosteronism does not always cause hypokalaemia. This is explained by the ‘renal potassium switch’ mechanism ( Figure 1), which involves the paradoxical actions of aldosterone on potassium; for example, aldosterone increases sodium reabsorption in states of low circulating volume without significantly altering potassium balance, but it also increases serum potassium excretion in high potassium states without affecting sodium balance. This paradoxical action all depends on the sodium delivery to the aldosterone-sensitive distal nephron (collecting duct) which is generated by the sodium-chloride co-symporter (NCC) in the early distal convoluted tubule. Activation of this ‘switch’ is by phosphorylation of NCC by the WNK/SPAK/OSR1 pathway 17, 18 and is done by aldosterone in response to low or high serum potassium i.e. NCC is maximally phosphorylated when serum potassium is <2.5 mmol/l and not at all phosphorylated when serum potassium is >5.2 mmol/l 19 . In states of decreased circulating volume, ENaC activity is increased due to the effects of excess aldosterone (which generates a sufficient intracellular electrochemical gradient to cause active transport of potassium from blood via Na +K +-ATPase which would be passively excreted into the tubular lumen by ROMK and BK channels in the Principal cell). Whether this generates an effect on potassium or not depends on the integrated activity of the entire distal nephron. In a state of low circulating volume, NCC in the early DCT is ‘switched on’ which results in increased reabsorption of sodium and chloride in the early DCT and, along with sodium reabsorption in the PCT, a net increase of sodium reabsorption from the kidney occurs. As a result, sodium delivery to the aldosterone sensitive distal nephron (collecting duct) is decreased which offsets the effects of ENaC and potassium excretion is therefore unchanged. This results in a state of hyperaldosteronism without hypokalaemia.

NCC Phosphorylation downstream and changes in urinary potassium (renal potassium switch).

In states of hyperaldosteronism and volume depletion the renal potassium switch is ‘active’. Angiotensin-II (ang-II) stimulates Kir4.1/5.1 to hyperpolarise the basolateral membrane potential and lowers intracellular chloride. This action activates WNK1 (With-no-lysine-kinase-1) and WNK4 (With-no-lysine-kinase-4) by phosphorylation which subsequently phosphorylates SPS1-related proline / alanine-rich kinase (SPAK) and oxidative stress-responsive kinase (OSR1) which, again, phosphorylates the sodium chloride co-symporter (NCC). NCC then avidly reabsorbs sodium (and chloride) back into the body in the early part of the distal convoluted tubule (DCT1). This results in reduced tubular sodium delivery to the collecting duct. Subsequently there is less sodium for the Epithelial sodium Channel (ENaC) to reabsorb and its action is offset. ENaC usually reabsorbs sodium and, via an electrochemical gradient made by sodium-potassium-ATPase, potassium is normally excreted into the tubular lumen by ROMK (Renal Outer Medulla Potassium channel) and BK (Big Potassium/Maxi-K channel) and eliminated from the body. When ENaC is less active, as a consequence of less tubular sodium delivery, less potassium is excreted. This results in a state of hyperaldosteronism with a normal serum potassium. In states of hyperaldosteronism and normal cardiovascular volume (in response to high serum potassium) the switch is ‘inactive’. NCC is not phosphorylated which results in more distal sodium delivery to the collecting duct and subsequent ENaC activation resulting in excretion of potassium into the tubular lumen and a state of hypokalaemia 17, 18 . Arrows represent the direction of movement of electrolytes. Red arrows reflect a reduction in movement and green arrows represent an increase in movement. CLC-Kb, chloride voltage-gated channel Kb; Kir4.1/5.1, inwardly rectifying potassium channel 4.1; AT1R, type 1 angiotensin receptor.

 Histopathological evidence of tubulopathy

There are two studies so far (one in pre-print form) to look at renal histopathology on post-mortem findings in SARS-CoV-2 patients who died of the disease (9 of the 26 had pre-morbid clinical kidney injury signs) 20, 21 . The first demonstrated prominent proximal tubule injury (observed in all 26 patients) with frank necrosis observed in some specimens and three patients had high creatinine phosphokinase and pigmented casts on light microscopy, probably representing rhabdomyolysis. There was occasional distal tubule and collecting duct swelling with some interstitial oedema and virus particles were seen in seven of the specimens on electron microscopy in proximal tubule epithelial cells and the podocyte, both of which are the only sites of renal ACE2 expression 20 . The second post-mortem case series in (currently in pre-print) examined six post-mortem renal histopathology samples of patients who died with SARS-CoV-2 infection 21 . All specimens had histopathological evidence of acute tubular necrosis, two patients had severe lymphocytic infiltration of the tubulointerstitium and SARS-CoV-2 nucleocapsid antigens were observed in renal tubule cells. Transmission electron microscopy was used in samples from two different patients, both of which demonstrated the presence of virions and virus-like particles in renal cells and these cells were markedly swollen with mitochondrial, lysosomal and endoplasmic reticulum expansion. These finding suggest that SARS-CoV-2 directly infects kidneys and specifically infects and damages kidney tubules. Furthermore, strong CD68 + macrophage presence and C5b-9 deposition seen in the tubulointerstitium of all samples (yet absent in the rest of the kidney tissue and very little in the glomeruli and capillaries in two patients) suggest that further tubular damage occurs as a consequence of macrophage recruitment and C5b-9 activation and deposition. It would be logical to suggest that histopathological evidence of damage to tubular cells would result, clinically, as a tubulopathy, of which we know hypokalaemia is a recognised complication and these case series are histopathological evidence to support this suggestion.

Finally, we know that TMPRSS2 primes SARS-CoV-2 to gain cellular entry and TMPRSS2 is only detectable (in low levels) at the S3 section of the proximal convoluted tubule in the kidney 22 . It is therefore assumed that this is one way in which the kidney is ‘infected’ by the virus and reiterates the probability of direct virus-induced tubular damage. Various case series have demonstrated the virus in urine 23, 24 and it is unclear as to how it enters the tubular lumen and whether this is via the apical membrane of tubule cells. However, one study did look at the presence of SARS-CoV-2 in bodily fluids over time and did not detect the virus in urine in any of the nine patients studied 25 . A couple of case reports have demonstrated that the virus may affect the kidney in other ways which may be an alternative explanation for the entry of virus into the urine 26, 27 . Collapsing focal segmental glomerulosclerosis (FSGS) has been described twice in the literature so far in patients of African or African American origin and both of these patients demonstrated severe tubular injury. It was noted that severe acute tubular necrosis (ATN) was observed in the absence of haemodynamic compromise and severe pulmonary involvement suggesting that the tubulopathy was not ischaemic and more likely to be because of either direct viral toxicity or cytokine-mediated damage.

 Discussion

The data from China and evidence from the SARS-CoV case series provide good clinical justification to monitor potassium levels in patients infected with SARS-CoV-2. We do need to see this clinical finding replicated in multi-centres to be able to make definitive conclusions about this clinical sequela. Although hyperkalaemia can occur for many reasons in patients with SARS-CoV-2 infection, the incidence of ventricular fibrillation has been shown to be five-fold higher in patients with hypokalaemia compared to those with hyperkalaemia 12 .

Based on evidence of significant urine potassium wasting which can be prolonged, we suggest checking the transtubular potassium gradient (TTKG) in patients with SARS-CoV-2 infection. This would help identify those at risk of severe or prolonged hypokalaemia and prompt pre-emptive cautious electrolyte monitoring and replacement which should help reduce the risk of hypokalaemic complications which can be fatal. The TTKG is easily measured and only requires measurements of serum and urine osmolality and potassium (urine potassium/serum potassium)/(urine osmolality/ serum osmolality). The estimation is relatively accurate providing the urine is not dilute and that urine sodium concentration is >25 mmol/l so that distal sodium delivery is not limiting 28 .

Measuring components of the renin-angiotensin-aldosterone pathway would help us to identify the involvement of the SARS-CoV-2 virus; however, measuring these components in the acute setting has its limitations. The RAS system is heavily influenced by a multitude of factors. Many of the patients with SARS-CoV-2 infection are critically unwell and often present to hospital in states of low cardiovascular volume. It has been recommended that patients with ARDS also be kept in a relative state of volume depletion as to not worsen pulmonary interstitial oedema and thus oxygenation. Both of these factors would typically result in RAS activation and could be very misleading when determining virus-related RAS pathway involvement. Some studies have shown that low urine pH (causing acidic urine) can be a predictor of RAS activation 29 so future studies determining RAS system involvement of SARS-CoV-2 infection should, as well as TTKG, also consider urine pH as an early marker of RAS system activation.

Potassium levels <3.0 mmol/l can be arrhythmogenic and specifically can cause QTc interval prolongation, torsade de pointes, ventricular fibrillation and sudden cardiac death 30 . This is particularly relevant for a couple of reasons. First, many of the drugs currently undergoing clinical trials in SARS-CoV-2 patients prolong the QTc interval (hydroxychloroquine 31 , azithromycin 31 , favipiravir, lopinavir/ritonavir and fingolimod: NCT04280588) and some drugs also risk hypokalaemia which may worsen pre-existing electrolyte disturbance (e.g. methylprednisolone: NCT04273321, NCT04263402; thalidomide: NCT04273529, NCT04273581; and bevacizumab: NCT04275414). Second, cardiac involvement in SARS-CoV-2 is high (44.4% of infected patients admitted to ICU experienced an arrhythmia). Induction of arrhythmias can be due to multi-factorial aetiologies of cardiac injury in SARS-CoV-2 patients such as hypoxia-mediated, direct tissue damage, cytokine-storm syndrome, worsening coronary perfusion and the direct effects of medications 32 . Both of these factors really emphasise the importance of maintaining normokalaemia in these patients to reduce morbidity and mortality.

In addition to the arrhythmogenic effects of both the SARS-CoV-2 cardiac sequelae and various clinical trial drugs, many patients are being given diuretics to improve the oxygenation in ARDS, which also risks hypokalaemic complications. If diuretics are to be used, it would be wise to consider potassium-sparing agents in hypokalaemic patients to reduce the cardiac complications of worsening hypokalaemia that can occur with those that are not potassium sparing.

It would be logical that with clear histopathological data suggesting tubular injury, hypokalaemia is to be expected in patients infected with SARS-CoV-2 33 . Tubular injury seems to be multifactorial in these patients; ATN from SIRS/Cytokine Storm Syndrome, peritubular congestion, virion invasion, drug toxicity and pigment-cast nephropathy from rhabdomyolysis and therefore difficult to avoid.

The data on outcomes in cardiac arrest for SARS-CoV-2 patients is unfortunately poor. Chinese data suggests that in a series of 136 patients who underwent resuscitation efforts, return of spontaneous circulation was only achieved in 18 (13.2%) and only four patients were alive at 30 days 34 . The strong association of hypokalaemia with arrhythmia and sudden cardiac death reiterates the importance of vigilance for detection and treatment of this electrolyte disturbance during and after admission given such poor outcomes when spontaneous circulation is lost.

To truly know the extent of involvement of the RAS pathway as a potential cause of hypokalaemia in SARS-CoV-2 patients, further studies require measurement of all components of the RAS pathway. Until we know this, we cannot make definite conclusions about the mechanisms of hypokalaemia in these patients outside of the histopathological evidence of tubulopathy published, of which multiple aetiological factors are likely.

 Data availability

No data are associated with this article.

 Chen JY Qiao K Liu F : Lung transplantation as therapeutic option in acute respiratory distress syndrome for COVID-19-related pulmonary fibrosis. Chin Med J (Engl). 2020. 32251003 10.1097/CM9.0000000000000839 Inciardi RM Lupi L Zaccone G : Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. 32219357 10.1001/jamacardio.2020.1096 Mao L Jin H Wang M : Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;e201127. 32275288 10.1001/jamaneurol.2020.1127 7149362 Wang F Wang H Fan J : Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology. 2020. 32247022 10.1053/j.gastro.2020.03.055 7118654 Riphagan S Gomez X Gonzalez-Martinez C : Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607–1608. 32386565 10.1016/S0140-6736(20)31094-1 7204765 Ronco C Reis T : Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nature Rev Nephrol. 2020;16(6):308–310. 32273593 10.1038/s41581-020-0284-7 7144544 Sparks M South A Welling P : Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19. Clin J Am Soc Nephrol. 2020;15(5):714–716. 32220930 10.2215/CJN.03530320 South AM Tomlinson L Edmonson D : Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020;16(6):305–307. 32246101 10.1038/s41581-020-0279-4 7118703 Wrapp D Wang N Corbett KS : Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263. 32075877 10.1126/science.abb2507 7164637 Kuba K Imai Y Rao S : A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus- induced lung injury. Nat Med. 2005;11(8):875–879. 16007097 10.1038/nm1267 7095783 Crop MJ Hoorn EJ Lindemas J : Hypokalemia and subsequent hyperkalemia in hospitalized patients. Nephrol Dial Transplant. 2007;22(12):3471–3477. 17848395 10.1093/ndt/gfm471 Clausen TG Brocks K Ibsen H : Hypokalemia and Ventricular Arrhythmias in Acute Myocardial Infarction. Acta Med Scand. 1988;224(6):531–537. 3207065 10.1111/j.0954-6820.1988.tb19623.x Kjeldsen K : Hypokalemia and sudden cardiac death. Exp Clin Cardiol. 2010;15(4):e96–e99. 21264075 3016067 Chen D Xiaokun L Qifa S : Hypokalemia and Clinical Implications in Patients with Coronavirus Disease 2019 (COVID-19). MedRxiv. 2020; 10.1101/2020.02.27.20028530 Tsang OTY Tsang TN Choi KW : Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis. 2003;9(11):1381–7. 14718079 10.3201/eid0911.030400 3035547 Guan WJ Ni ZY Hu Y : Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. 32109013 10.1056/NEJMoa2002032 7092819 Kamel SK Schreiber M Halperin ML : Renal potassium physiology: integration of the renal response to dietary potassium depletion. Kidney Int. 2018;93(1):41–53. 29102372 10.1016/j.kint.2017.08.018 Mabillard H Sayer JA : The Molecular Genetics of Gordon Syndrome. Genes. 2019;10(12):986. 31795491 10.3390/genes10120986 6947027 Welling PA : Roles and Regulation of Renal K Channels. Annu Rev Physiol. 2016;78:415–435. 26654186 10.1146/annurev-physiol-021115-105423 Su H Yang M Wan C : Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020; S0085-2538(20)30369-0. In press. 32327202 10.1016/j.kint.2020.04.003 7194105 Diao B Wang C Feng Z : Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. MedRxiv preprint. 2020. 10.1101/2020.03.04.20031120 Hoffman M Schroeder S Kleine-Weber H : SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–280. 10.1016/j.cell.2020.02.052 Peng L Liu J Xu W : 2019 Novel Coronavirus can be detected in urine, blood, anal swabs and oropharyngeal swabs samples. MedRxiv preprint. 2020. 10.1101/2020.02.21.20026179 Wang L Li X Chen H : SARS-CoV-2 infection does not significantly cause acute renal injury: an analysis of 116 hospitalized patients with COVID-19 in a single hospital, Wuhan, China. medRxiv preprint. 2020. 10.1101/2020.02.19.20025288 Wölfel R Corman VM Guggemos W : Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465–469. 32235945 10.1038/s41586-020-2196-x Kissling S Rotman S Gerber C : Collapsing glomerulopathy in a COVID-19 patient. Kidney Int. 2020; S0085-2538(20)30395-1. 32471639 10.1016/j.kint.2020.04.006 7156952 Gaillard F Ismael S Sannier A : Tubuloreticular inclusions in COVID-19-related collapsing glomerulopathy. Kidney Int. 2020; S0085-2538(20)30499-3. 32471641 10.1016/j.kint.2020.04.022 7185005 Elisaf M Rizos E Siamopoulos K : Potassium excretion indices in the diagnostic approach to hypokalaemia. QJM. 2000;93(5):318–319. 10825410 10.1093/qjmed/93.5.318 Ogawa S Nako K Okamura M : Lower urinary pH is useful for predicting renovascular disorder onset in patients with diabetes. BMJ Open Diabetes Res Care. 2015;3(1):e000097. 26157584 10.1136/bmjdrc-2015-000097 4486685 Widimsky P : Hypokalaemia and the heart. E-journal of Cardiology Practice. 2008;7(9). Reference Source Gautret P Lagier JC Parola P : Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949. 32205204 10.1016/j.ijantimicag.2020.105949 7102549 Zheng YY Ma YT Zhang JY : COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259–260. 10.1038/s41569-020-0360-5 Sebastian A McSherry E Morris RC Jr : Renal Potassium Wasting in Renal Tubular Acidosis (RTA): Its Occurrence in Types 1 and 2 RTA Despite Sustained Correction of Systemic Acidosis. J Clin Invest. 1971;50(3):667–78. 5101785 10.1172/JCI106537 291975 Shao F Xu S Ma X : In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. Resuscitation. 2020.151:18–23. 10.1016/j.resuscitation.2020.04.005 10.5256/f1000research.26961.r64575 Reviewer response for version 1 Welling Paul 1 Referee Johns Hopkins University, School of Medicine, Baltimore, MD, USA

Competing interests: No competing interests were disclosed.

 26 6 2020 Copyright: © 2020 Welling P 2020 This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. recommendation reject

As pointed out by this review, the evidence for hypokalemia in COVID-19 is weak, promulgated by a single unpublished article that was not corroborated by larger series studies. My chief concern about the review, is that it amplifies the myth. Furthermore, the frequent use of loop diuretics in ARDS, which cause hypokalemia, makes a causal connection between the development of hypokalemia and COVID-19 precarious.

At the very least, the title should be changed to minimize the connection between hypokalemia and COVID-19.  

Paragraph 1 is somewhat misleading.  Although COVID-19 does have an array of different sequela, acute respiratory distress syndrome (ARDS) seems to be the most common serve form of the disease. The first paragraph should provide an incidence of this and the other sequela. Reference to large studies from China, Europe and North American should be cited.

Paragraph 2 The statement “SARS-CoV-2 may affect the kidneys directly and indirectly by both renal and renin-angiotensin-aldosterone system (RAS) involvement,” has no factual basis. There are a few small studies that demonstrate that SARS-CoV-2 can infect the kidney but it is presently unclear if this is a key mechanism of AKI in COVID19.

Paragraph 3 Provide a reference to Mas receptor on type 2 alveolar epithelial cells as stated.

Paragraph 3 last sentence. This is evidence for SARS-COV, not SARS-COV2

Provide a reference to “hyperaldosteronism does not always cause hypokalaemia.” Although “Switch” activation has been a popular explanation for this, it has never been proven. Perhaps, the authors could cite clinical studies, demonstrating the development of severe hypokalemia in normokalemic PA patients following thiazide administration as evidence.

The limitations of TTKG should be articulated.

Is the topic of the opinion article discussed accurately in the context of the current literature?

Partly

Are arguments sufficiently supported by evidence from the published literature?

Partly

Are all factual statements correct and adequately supported by citations?

Partly

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Partly

Reviewer Expertise:

I am an expert on molecular underpinnings of potassium balance and electrolyte disorders. I coined the "potassium switch"

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.